ReviewFrontiers in physiology2023
Gut microbiota dependant trimethylamine N-oxide and hypertension.
Review in Frontiers in physiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Impacts of intestinal microbiota metabolite trimethylamine N-oxide on cardiovascular disease: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Gut microbiota changes in patients with hypertension: A systematic review and meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2023Pooled it
- Gut Microbiota in Metabolic Syndrome: Differences in Microbial Signatures and Clinical Profiles.Medicina (Kaunas, Lithuania) · 2026Review
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- [Mechanisms of gutZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Comparative analysis of pathways induced by TMAO and TNF-α in human microvascular endothelial cells.Scientific reports · 2026Article
- Gut microbiota-derived polyamine pathways associated with mean blood pressure.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Multiomics: the intersection of personalized nutrition in cardiometabolic diseases.Journal of translational medicine · 2026Review
- Value of Multiomics Over Clinical Risk Factors in Hypertension Prediction.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Interconnection between gut microbial metabolites and mitochondrial ROS production: implications for cellular health.Molecular and cellular biochemistry · 2026Review
- Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies.International journal of hypertension · 2026Review
- Gut Microbiota and Hypertension: Mechanisms, Drug Interactions, and Translational Directions for Individualized Therapy.International journal of general medicine · 2026Review
- Microbiome and Heart Failure: A Comprehensive Review of Gut Health and Microbiota-Derived Metabolites in Heart Failure Progression.Medical sciences (Basel, Switzerland) · 2025Review
- Integrated mechanisms linking sodium-potassium imbalance to salt-sensitive hypertension.Physiological reports · 2025Review
- Investigation of ED4 supplementation on cardiovascular parameters in rats with elevated systemic TMAO.NPJ science of food · 2025Article
- Food as Medicine for Hypertension: Microbiota as Mediators.Hypertension (Dallas, Tex. : 1979) · 2025Review
- Effects of mobile application-based dietary recommendations on patients aged 50 and older with type 2 diabetes, obesity, and hypertension in Gwangju, South Korea: a pilot trial.Nutrition research and practice · 2025Article
- Targeting Gut Microbiota to Combat Vascular Aging and Cardiovascular Disease: Mechanisms and Therapeutic Potential.Nutrients · 2025Review
- Probiotics and Prebiotics in Post-Myocardial Infarction Rehabilitation: Mechanisms, Benefits, and Future Directions.Current nutrition reports · 2025Review
- "Gut Microbiota as a Therapeutic Target for Hypertension: Challenges and Insights for Future Clinical Applications" "Gut Microbiota and Hypertension Therapy".Current hypertension reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The human gut microbiota environment is constantly changing and some specific changes influence the host's metabolic, immune, and neuroendocrine functions. Emerging evidence of the gut microbiota's role in the development of cardiovascular disease (CVD) including hypertension is remarkable. There is evidence showing that alterations in the gut microbiota and especially the gut-dependant metabolite trimethylamine N-oxide is associated with hypertension. However, there is a scarcity of literature addressing the role of trimethylamine N-oxide in hypertension pathogenesis. In this review, we discuss the impact of the gut microbiota and gut microbiota dependant trimethylamine N-oxide in the pathogenesis of hypertension. We present evidence from both human and animal studies and further discuss new insights relating to potential therapies for managing hypertension by altering the gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.